JBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jade Biosciences Inc (JBIO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with increasing price targets, a promising pipeline in a growing market, and positive sentiment around its upcoming Phase 1 data. While the financials are currently weak, the long-term growth potential outweighs the short-term negatives.
The MACD is positively expanding, indicating bullish momentum. RSI is neutral at 51.188, and moving averages are converging, suggesting no strong trend. Key support is at 13.133, and resistance is at 14.844. The pre-market price of 13.95 is near the pivot point of 13.988, indicating a balanced entry point.
Analysts have raised price targets significantly, with targets ranging from $23 to $40, citing the potential of JADE101 in a booming IgAN market. Upcoming Phase 1 data in Q2 is a key catalyst. The company is positioned to benefit from a growing autoimmune market.
Weak financial performance with no revenue and negative EPS (-0.64). Insider and hedge fund activity is neutral, indicating no strong institutional support.
In 2025/Q3, revenue remained at 0, net income improved by 55.05% YoY to -$25.18M, and EPS dropped by -96.75% YoY to -0.64. Gross margin remains at 0%. The financials indicate a company in the early stages of development with no current profitability.
Analysts are highly bullish, with multiple firms raising price targets and maintaining Buy ratings. The highest target is $40, and the lowest is $23. Analysts are optimistic about the company's JADE101 drug and its potential in the IgAN market.
